Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

Sanofi Consumer Health Care India Ltd, the pharmaceutical company that makes Combiflam among other consumer drugs, announced to sell 26% of its equity shares to Opal Bidco SAS along with U.S.-based ...

Sale to US private equity firm Clayton Dubilier & Rice comes as investors anticipate more and larger European PE buyouts ...

Sanofi reported stronger-than-expected third-quarter earnings on Friday, driven by early vaccine sales and robust performance ...

Sanofi reported third-quarter earnings and sales that beat analysts' expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and growing demand for ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive ...

“Powered by the twin forces of guilt and technology,” Kirby writes, higher tips at restaurants became more standardized as ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

- Subdued session overall but looking forward to an action-pack week ahead. Session saw cautious tone as market's focus on ...